U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07642557) titled 'Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)' on May 19.
Brief Summary: Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.
Study Start Date: July 10
Study Type: OBSERVATIONAL
Condition:
Chronic Spontaneous Urticaria
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Pub...